Citations

Showing 10 of 108081 citations.

Symptomatic non-stenotic carotid disease: current challenges and opportunities for diagnosis and treatment
Kappelhof, Manon , Kallmes, David F. , Brinjikji, Waleed , Goyal, Mayank , Kappelhof, Manon , Ganesh, Aravind , Brinjikji, Waleed , Goyal, Mayank , Ospel, Johanna M. , Ganesh, Aravind

Mayo Clinic

Journal of NeuroInterventional Surgery | April 17, 2023 | Volume: 16 | Issue: 4 | Pages: 418-424

10.1136/jnis-2022-020005 | PMID 37068939 Get It

Symptomatic non-stenotic carotid plaques (SyNC) are an under-researched and under-recognized source of stroke. Various imaging markers of non-stenotic carotid plaques that are associated with stroke risk have been identified, but these causal relationships need to be confirmed in additional prospective studies. Currently, there exists neither a standardized SyNC definition nor a dedicated set of imaging protocols, although researchers have started to address these shortcomings. Moreover, many neuroradiologists are still unaware of the condition, and hence do not comment on high-risk plaque features other than stenosis in their reports. Regarding SyNC treatment, scant data exist as to whether and to what extent medical, interventional and surgical treatments could influence the course of the disease; the relative lack of data on the ‘natural’ history of untreated SyNC makes treatment comparisons difficult. In our opinion, endovascular SyNC treatment represents the most promising treatment option for SyNC, since it allows for targeted elimination of the embolic source, with few systemic side effects and without the need for general anesthesia. However, currently available carotid devices are designed to treat stenotic lesions, and thus are not optimally designed for SyNC. Developing a device specifically tailored to SyNC could be an important step towards establishing endovascular SyNC treatment in clinical practice. In this review, we provide an overview of the current state of evidence with regard to epidemiological, clinical and imaging features of SyNC, propose a SyNC definition based on imaging and clinical features, and outline a possible pathway towards evidence-based SyNC therapies, with a special focus on endovascular SyNC treatment.
National Institutes of Health grant funding for cerebrovascular diseases
Kobeissi, Hassan , Jabal, Mohamed Sobhi , Ghozy, Sherief , Naylor, Ryan M. , Kadirvel, Ramanathan , Brinjikji, Waleed , Kallmes, David F. , Arul, Santhosh , Kadirvel, Ram , Brinjikji, Waleed , Ghozy, Sherief , Kobeissi, Hassan

Mayo Clinic

Journal of NeuroInterventional Surgery | April 17, 2023 | Volume: 16 | Issue: 2 | Pages: 209-212

10.1136/jnis-2023-020374 | PMID 37068940 Get It

Background Federal research funding is highly sought after but may be challenging to attain. A clear understanding of funding for specific diseases, such as cerebrovascular disorders, might help researchers regarding which National Institutes of Health (NIH) institutes fund research into specific disorders and grant types. Objective To examine the current scope of NIH grant funding for cerebrovascular conditions. Methods The NIH-developed RePORTER was used to extract active NIH-funded studies related to cerebrovascular diseases through January 2023. Duplicate studies were removed, and projects were manually screened and labeled in subcategories as clinical and basic science and as research subcategories. Extracted data included total funding, grant types, institutions that received funding, and diseases studied. Python (version 3.9) and SciPy library were used for statistical analyses. Results We identified 1232 cerebrovascular projects across seven diseases with US$699 952 926 in total funding. The cerebrovascular diseases with the greatest number of grants were ischemic stroke (705, or 57.2% of all funded projects), carotid disease (193, or 15.7%), and hemorrhagic stroke (163, or 13.2%). R01 grants were the most common mechanism of funding (632 grants, or 51.3%). The National Institute of Neurological Disorders and Stroke (NINDS) funded the most projects (504 projects; US$325 536 405), followed by the National Heart, Lung, and Blood Institute (NHLBI) (376 projects; US$216 784 546). Conclusion Cerebrovascular disease receives roughly US$700 million in NIH funding. Ischemic stroke accounts for the majority of NIH-funded cerebrovascular projects, and R01 grants are the most common funding mechanism. Notably, NHLBI provides a large proportion of funding, in addition to NINDS.
Daratumumab-lenalidomide and daratumumab-pomalidomide in relapsed lenalidomide-exposed or refractory multiple myeloma
Abdulazeez, Mays F , Sher, Taimur , Alegria, Victoria R., Warsame, Rahma , Rasheed, Ahsan , Kourelis, Taxiarchis , Kapoor, Prashant , Dingli, David , Hayman, Suzanne R. , Reeder, Craig B. , Chanan‐Khan, Asher , Alhaj Moustafa, Muhamad, Warsame, Rahma M, Chanan-Khan, Asher A., Dingli, David , Moustafa, Muhamad Alhaj , Parrondo, Ricardo D , Roy, Vivek , Fonseca, Rafaël , Gonsalves, Wilson I. , Buadi, Francis K. , Ailawadhi, Sikander

Mayo Clinic

Anti-Cancer Drugs | April 17, 2023 | Volume: 35 | Issue: 1 | Pages: 63-69

10.1097/cad.0000000000001520 | PMID 37067996 Get It

Daratumumab is an anti-CD38 mAb, used frequently in combination with lenalidomide and pomalidomide. No studies compared daratumumab plus lenalidomide and dexamethasone (DRd) to daratumumab plus pomalidomide and dexamethasone (DPd) in lenalidomide-exposed multiple myeloma. We identified 504 consecutive multiple myeloma patients who received daratumumab at Mayo Clinic between January 2015 and April 2019. We excluded patients who received daratumumab in the first line, received more than four lines of therapy prior to daratumumab use, did not receive lenalidomide prior to daratumumab, or had an unknown status of lenalidomide exposure, and patients who received daratumumab combinations other than DRd or DPd. We examined the impact of using DRd compared to DPd on progression-free survival (PFS) and overall survival (OS) in patients with relapsed/refractory multiple myeloma. Out of 504 patients, 162 received DRd or DPd and were included; 67 were lenalidomide-exposed and 95 were lenalidomide-refractory. DRd was used in 76 (47%) and DPd in 86 (53%) patients. In lenalidomide-exposed multiple myeloma, there was no difference in median PFS; 34.2 months [95% confidence interval (CI), 22.8–44.6] for DRd compared to 25.2 months (95% CI, 4.9–35.3) for DPd, P = 0.2. In lenalidomide-refractory multiple myeloma, there was no difference in median PFS; 18.6 months (95% CI, 13–32) for DRd compared to 9 months (95% CI, 5.2–14.6) for DPd, P = 0.09. No difference in median OS was observed in DRd compared to DPd. Our study shows combining daratumumab with lenalidomide in patients with prior lenalidomide use is a viable and effective treatment option.
Are 4D Motion Sensors Valid and Reliable for Studying Baseball Pitching?
Loushin, Stacy R. , Verhoeven, Martijn, Christoffer, Daniel J., Camp, Christopher L. , Kaufman, Kenton R.

Mayo Clinic

The American Journal of Sports Medicine | April 17, 2023 | Volume: 51 | Issue: 6 | Pages: 1608-1614

10.1177/03635465231166423 | PMID 37067847 Get It

Background: Baseball pitching injuries are on the rise. Inertial measurement units (IMUs) provide immediate feedback to players and coaches, allowing for collection outside of the traditional laboratory setting with real-world application. The 4D Motion system provides kinematics throughout the pitching motion and may be beneficial for individualized programs in the throwing athlete. A systematic analysis of these sensors has not been completed. Purpose: To evaluate the validity of the 4D Motion IMU system for analyzing the baseball pitching motion compared with marker-based motion capture, and evaluate the internal reliability and consistency of the device. Study Design: Controlled laboratory study. Methods: Ten high school pitchers participated in this study (10 male; 9 right-hand dominant; mean age, 16.6 ± 1.3 years; mean body mass index, 24.1 ± 3.9). Participants were simultaneously outfitted with six 4D Motion IMU sensors and retroreflective markers. The pitchers threw fastballs at maximum effort off a mound at the standard height and distance. A comparison was made between the IMUs and corresponding motion capture values for shoulder external rotation, elbow flexion, chest extension, pelvis and chest rotation velocity, and rotation acceleration. Results: Significant differences were found for 5 of 7 metrics analyzed. The IMU overreported most metrics, except for elbow flexion and pelvis rotation angular acceleration, where both positive and negative errors were observed. The root mean square error and percentage errors indicated smaller discrepancies for chest extension (4°± 5°) and pelvis (38 ± 19 deg/s) and chest (96 ± 42 deg/s) rotation velocity, with elbow flexion having the largest variance (21°± 9°). Conclusion: The values of the 4D Motion IMU system should not be considered equivalent when compared with marker-based motion capture studies. The system lacked internal consistency and reliability, with angular velocities being the most consistent. Caution should be used when using the metrics provided by an IMU-based system for individualized monitoring. Clinical Relevance: If found valid and reliable, IMUs could be used for longitudinal workload monitoring, individualized throwing and rehabilitation programs, and ultimately injury prevention. This study demonstrates that the data obtained from a 4D Motion system using Gen 3 sensors are not equivalent to the data obtained from a marker-based motion capture system.
Epicardial Fat in Heart Failure with Preserved Ejection Fraction: Bad Actor or Just Lying Around?
Oduah, Mary-Tiffany , Sundaram, Varun , Reddy, Yogesh N.V. , Reddy, Yogesh Nv, Nishimura, Rick

Mayo Clinic

Cardiac Failure Review | April 17, 2023 | Volume: 9 | Issue: No issue available | Pages: No page available

10.15420/cfr.2022.25 | PMID 37397241 Get It

Heart failure with preserved ejection fraction (HFpEF) is increasingly recognised to be strongly associated with obesity and abnormalities in fat distribution. Epicardial fat has been associated with abnormal haemodynamics in HFpEF, with potential for direct mechanical effects on the heart causing constriction-like physiology and local myocardial remodelling effects from secretion of inflammatory and profibrotic mediators. However, patients with epicardial fat generally have more systemic and visceral adipose tissue making determination of causality between epicardial fat and HFpEF complex. In this review, we will summarise the evidence for epicardial fat being either directly causal in HFpEF pathogenesis or merely being a correlate of worse systemic inflammatory and generalised adiposity. We will also discuss therapies that directly target epicardial fat and may have potential for treating HFpEF and elucidating the independent role of epicardial fat in its pathogenesis.
It is time to expand the fatty liver disease community of practice
Lazarus, Jeffrey V. , Kopka, Christopher J. , Younossi, Zobair M. , Allen, Alina M. , Lazarus, Jeffrey V , Allen, Alina M , Kopka, Christopher J

Mayo Clinic

Hepatology | April 17, 2023 | Volume: 78 | Issue: 5 | Pages: 1325-1328

10.1097/hep.0000000000000411 | PMID 37067242 Get It

Hyperlactatemia and poor outcome After postcardiotomy veno-arterial extracorporeal membrane oxygenation: An individual patient data meta-Analysis
Biancari, Fausto , Perrotti, Andréa , Cho, Sung‐Min , Kang, Jin Kook, Welp, Henryk , Jónsson, Kristján , Pérez, Francisco José Hernández, Alkhamees, Khalid , Loforte, Antonio , Spadaccio, Cristiano , Pettinari, Matteo , Mäkikallio, Timo , Sahli, Sebastian D. , L’Acqua, Camilla , AlBarak, Mohammed M, Laimoud, Mohamed , Samalavičius, Robertas , Alonso-Fernández-Gatta, Marta , Spahn, Donat R., Fiore, Antonio , Gatti, Giuseppe , Rosato, Stefano , L'Acqua, Camilla , Arafat, Amr A , Laimoud, Mohamed , Djordjevic, Ilija , Krasivskyi, Ihor , Cho, Sung-Min , Jónsson, Kristján , Loforte, Antonio , Pettinari, Matteo , Fiore, Antonio , Sahli, Sebastian D , Alonso-Fernandez-Gatta, Marta , Samalavicius, Robertas , Kaserer, Alexander , Ruggieri, Vito Giovanni , Kang, Jin Kook , Dalén, Magnus , Ragnarsson, Sigurður , Gatti, Giuseppe , Lechiancole, Andrea , Rosato, Stefano , Mariscalco, Giovanni , Albabtain, Monirah Abdulrahman , Djordjevic, Ilija , Krasivskyi, Ihor , Puodžiukaitė, Lina

Mayo Clinic

Perfusion | April 17, 2023 | Volume: 39 | Issue: 5 | Pages: 956-965

10.1177/02676591231170978 | PMID 37066850 Get It

Introduction Postcardiotomy veno-arterial extracorporeal membrane oxygenation (V-A-ECMO) is associated with significant mortality. Identification of patients at very high risk for death is elusive and the decision to initiate V-A-ECMO is based on clinical judgment. The prognostic impact of pre-V-A-ECMO arterial lactate level in these critically ill patients has been herein evaluated. Methods A systematic review was conducted to identify studies on postcardiotomy VA-ECMO for the present individual patient data meta-analysis. Results Overall, 1269 patients selected from 10 studies were included in this analysis. Arterial lactate level at V-A-ECMO initiation was increased in patients who died during the index hospitalization compared to those who survived (9.3 vs 6.6 mmol/L, p < 0.0001). Accordingly, in hospital mortality increased along quintiles of pre-V-A-ECMO arterial lactate level (quintiles: 1, 54.9%; 2, 54.9%; 3, 67.3%; 4, 74.2%; 5, 82.2%, p < 0.0001). The best cut-off for arterial lactate was 6.8 mmol/L (in-hospital mortality, 76.7% vs. 55.7%, p < 0.0001). Multivariable multilevel mixed-effect logistic regression model including arterial lactate level significantly increased the area under the receiver operating characteristics curve (0.731, 95% CI 0.702–0.760 vs 0.679, 95% CI 0.648–0.711, DeLong test p < 0.0001). Classification and regression tree analysis showed the in-hospital mortality was 85.2% in patients aged more than 70 years with pre-V-A-ECMO arterial lactate level ≥6.8 mmol/L. Conclusions Among patients requiring postcardiotomy V-A-ECMO, hyperlactatemia was associated with a marked increase of in-hospital mortality. Arterial lactate may be useful in guiding the decision-making process and the timing of initiation of postcardiotomy V-A-ECMO.
Natural Polyphenols—Resveratrol, Quercetin, Magnolol, and β-Catechin—Block Certain Aspects of Heroin Addiction and Modulate Striatal IL-6 and TNF-α
ElShebiney, Shaimaa , Elgohary, Rania , El-Shamarka, Marwa El-Sayed , Mowaad, Noha A. , Abulseoud, Osama A.

Mayo Clinic

Toxics | April 17, 2023 | Volume: 11 | Issue: 4 | Pages: 379

10.3390/toxics11040379 | PMID 37112606 Get It

We have examined the effects of four different polyphenols in attenuating heroin addiction using a conditioned place preference (CPP) paradigm. Adult male Sprague Dawley rats received heroin (alternating with saline) in escalating doses starting from 10 mg/kg, i.p. up to 80 mg/kg/d for 14 consecutive days. The rats were treated with distilled water (1 mL), quercetin (50 mg/kg/d), β-catechin (100 mg/kg/d), resveratrol (30 mg/kg/d), or magnolol (50 mg/kg/d) through oral gavage for 7 consecutive days, 30 min before heroin administration, starting on day 8. Heroin withdrawal manifestations were assessed 24 h post last heroin administration following the administration of naloxone (1 mg/kg i.p). Heroin CPP reinstatement was tested following a single dose of heroin (10 mg/kg i.p.) administration. Striatal interleukin 6 (IL-6) and tumor necrosis factor alpha (TNF-α) were quantified (ELISA) after naloxone-precipitated heroin withdrawal. Compared to the vehicle, the heroin-administered rats spent significantly more time in the heroin-paired chamber (p < 0.0001). Concomitant administration of resveratrol and quercetin prevented the acquisition of heroin CPP, while resveratrol, quercetin, and magnolol blocked heroin-triggered reinstatement. Magnolol, quercetin, and β-catechin blocked naloxone-precipitated heroin withdrawal and increased striatal IL-6 concentration (p < 0.01). Resveratrol administration was associated with significantly higher withdrawal scores compared to those of the control animals (p < 0.0001). The results of this study show that different polyphenols target specific behavioral domains of heroin addiction in a CPP model and modulate the increase in striatal inflammatory cytokines TNF-α and IL-6 observed during naloxone-precipitated heroin withdrawal. Further research is needed to study the clinical utility of polyphenols and to investigate the intriguing finding that resveratrol enhances, rather than attenuates naloxone-precipitated heroin withdrawal.
The Utility of Bronchoscopy in Hydralazine-Induced ANCA-Associated Vasculitis
Khosla, Atulya Aman , Saunders, Hollie , Helgeson, Scott A. , Hikida, Hiroshi Dean , Aslam, Nabeel , Salem, Fadi , Albadri, Sam , Baig, Hassan , Helgeson, Scott A , Hikida, Hiroshi , Salem, Fadi E , Baig, Hassan Z

Mayo Clinic

Case Reports in Pulmonology | April 15, 2023 | Volume: 2023 | Issue: No issue available | Pages: 1-4

10.1155/2023/1461011 | PMID 37095760 Get It

Hydralazine is a vasodilator used for the management of hypertension, heart failure, and hypertensive emergencies in pregnancy. It has been implicated in the causation of drug-induced lupus erythematosus (DLE) and rarely with ANCA-associated vasculitis (AAV), which may present as a pulmonary-renal syndrome and be rapidly fatal. Herein, we describe a case of hydralazine-associated AAV presenting as acute kidney injury with the use of early bronchoalveolar lavage (BAL) with serial aliquots to aid with diagnosis. Our case highlights how, in the correct clinical setting, BAL can act as a rapid diagnostic test to help guide quicker treatment to allow for better patient outcomes.
VE303, a Defined Bacterial Consortium, for Prevention of Recurrent Clostridioides difficile Infection
Louie, Thomas , Golan, Yoav , Khanna, Sahil , Bobilev, Dmitri, Erpelding, Nathalie, Fratazzi, Candida, Carini, Meg, Menon, Rajita , Ruisi, Mary, Faith, Jeremiah J. , Olle, Bernat , Li, Minran, Silber, Jeffrey L. , Pardi, Darrell S. , Norman, Jason M.

Mayo Clinic

JAMA | April 15, 2023 | Volume: 329 | Issue: 16 | Pages: 1356

10.1001/jama.2023.4314 | PMID 37060545 Get It

ImportanceThe effect of rationally defined nonpathogenic, nontoxigenic, commensal strains of Clostridia on prevention of Clostridioides difficile infection (CDI) is unknown.ObjectiveTo determine the efficacy of VE303, a defined bacterial consortium of 8 strains of commensal Clostridia, in adults at high risk for CDI recurrence. The primary objective was to determine the recommended VE303 dosing for a phase 3 trial.Design, Setting, and ParticipantsPhase 2, randomized, double-blind, placebo-controlled, dose-ranging study conducted from February 2019 to September 2021 at 27 sites in the US and Canada. The study included 79 participants aged 18 years or older who were diagnosed with laboratory-confirmed CDI with 1 or more prior CDI episodes in the last 6 months and those with primary CDI at high risk for recurrence (defined as aged ≥75 years or ≥65 years with ≥1 risk factors: creatinine clearance &amp;lt;60 mL/min/1.73 m2, proton pump inhibitor use, remote [&amp;gt;6 months earlier] CDI history).InterventionsParticipants were randomly assigned to high-dose VE303 (8.0 × 109 colony-forming units [CFUs]) (n = 30), low-dose VE303 (1.6 × 109 CFUs) (n = 27), or placebo capsules (n = 22) orally once daily for 14 days.Main Outcomes and MeasuresThe primary efficacy end point was the proportion of participants with CDI recurrence at 8 weeks using a combined clinical and laboratory definition. The primary efficacy end point was analyzed in 3 prespecified analyses, using successively broader definitions for an on-study CDI recurrence: (1) diarrhea consistent with CDI plus a toxin-positive stool sample; (2) diarrhea consistent with CDI plus a toxin-positive, polymerase chain reaction–positive, or toxigenic culture–positive stool sample; and (3) diarrhea consistent with CDI plus laboratory confirmation or (in the absence of a stool sample) treatment with a CDI-targeted antibiotic.ResultsBaseline characteristics were similar across the high-dose VE303 (n = 29; 1 additional participant excluded from efficacy analysis), low-dose VE303 (n = 27), and placebo (n = 22) groups. The participants’ median age was 63.5 years (range, 24-96); 70.5% were female; and 1.3% were Asian, 1.3% Black, 2.6% Hispanic, and 96.2% White. CDI recurrence rates through week 8 (using the efficacy analysis 3 definition) were 13.8% (4/29) for high-dose VE303, 37.0% (10/27) for low-dose VE303, and 45.5% (10/22) for placebo (P = .006, high-dose VE303 vs placebo).Conclusions and RelevanceAmong adults with laboratory-confirmed CDI with 1 or more prior CDI episodes in the last 6 months and those with primary CDI at high risk for recurrence, high-dose VE303 prevented recurrent CDI compared with placebo. A larger, phase 3 study is needed to confirm these findings.Trial RegistrationClinicalTrials.gov Identifier: NCT03788434